All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Morie A. Gertz, Mayo Clinic, Rochester, US. We asked, In the era of upfront quadruplets, is there still a role for allogeneic transplant?
In the era of upfront quadruplets, is there still a role for allogeneic transplant?
In this video, Gertz discusses the fall in allogeneic transplantation for patients with multiple myeloma in the US due to the increasing availability of less toxic agents, such as CAR T cells and bi-specific antibodies. Gertz also discusses the risk of chronic GvHD after transplant in multiple myeloma and long-term survival outcomes.
Novel risk score for predicting early relapse in patients with multiple myeloma
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure...
Challenges and future directions for access to cell therapies: A global perspective
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), a joint session titled "Access to novel cell therapies such as CAR...
Is there still a role in MM for auto-SCT after induction with a quadruplet combination?
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Luciano J. Costa, University of Alabama at Birmingham,...
Subscribe to get the best content related to multiple myeloma delivered to your inbox